Anixa Biosciences (ANIX)
Market Price (9/21/2026): $2.77 | Market Cap: $-Sector: Health Care | Industry: Biotechnology
Anixa Biosciences (ANIX)
Market Price (9/21/2026): $2.77Market Cap: $-Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Weak multi-year price returns2Y Excs Rtn is -53%, 3Y Excs Rtn is -94% | Key risksANIX key risks include [1] its complete dependence on successful clinical trial outcomes and subsequent regulatory approvals for its investigational products, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -53%, 3Y Excs Rtn is -94% |
| Key risksANIX key risks include [1] its complete dependence on successful clinical trial outcomes and subsequent regulatory approvals for its investigational products, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 9/17/2026
Anixa Biosciences (ANIX) stock has gained about 5% since 5/31/2026 because of the following key factors:
1. Continued Clinical Development without Major Catalysts.
Anixa Biosciences reported positive final Phase 1 data for its breast cancer vaccine, demonstrating that all primary endpoints were met, including safety, and that protocol-defined immune responses were generated in 74% of participants. Preparations for a Phase 2 trial are underway. Similarly, its ovarian cancer CAR-T therapy (lira-cel) advanced to the fifth and highest dose cohort in its ongoing Phase 1 clinical trial, with no dose-limiting toxicities observed to date and several patients surpassing one year of survival, including one beyond 28 months. While these are positive advancements for early-stage programs and extend patent protection in regions like Australia and Korea, they represent incremental progress rather than definitive commercial breakthroughs, leading to a largely stable stock price without significant upward momentum.
2. Persistent Lack of Revenue and Ongoing Operating Losses.
As a clinical-stage biotechnology company, Anixa Biosciences continued to report no revenue for fiscal Q3 2026 (ended July 31, 2026), a trend unchanged from the year-ago quarter. The company posted a net loss attributable to common shareholders of $(2.61) million for fiscal Q3 2026 and a net loss of $(7.69) million for the nine months ended July 31, 2026. Management has stated that near-term revenue from its therapeutics or vaccine programs is not anticipated. This ongoing lack of revenue and continued financial losses, typical for companies in this development stage, temper investor enthusiasm and limit significant stock appreciation.
Show more
Anixa Biosciences (ANIX) stock has gained about 5% since 5/31/2026 because of the following key factors:
1. Continued Clinical Development without Major Catalysts.
Anixa Biosciences reported positive final Phase 1 data for its breast cancer vaccine, demonstrating that all primary endpoints were met, including safety, and that protocol-defined immune responses were generated in 74% of participants. Preparations for a Phase 2 trial are underway. Similarly, its ovarian cancer CAR-T therapy (lira-cel) advanced to the fifth and highest dose cohort in its ongoing Phase 1 clinical trial, with no dose-limiting toxicities observed to date and several patients surpassing one year of survival, including one beyond 28 months. While these are positive advancements for early-stage programs and extend patent protection in regions like Australia and Korea, they represent incremental progress rather than definitive commercial breakthroughs, leading to a largely stable stock price without significant upward momentum.
2. Persistent Lack of Revenue and Ongoing Operating Losses.
As a clinical-stage biotechnology company, Anixa Biosciences continued to report no revenue for fiscal Q3 2026 (ended July 31, 2026), a trend unchanged from the year-ago quarter. The company posted a net loss attributable to common shareholders of $(2.61) million for fiscal Q3 2026 and a net loss of $(7.69) million for the nine months ended July 31, 2026. Management has stated that near-term revenue from its therapeutics or vaccine programs is not anticipated. This ongoing lack of revenue and continued financial losses, typical for companies in this development stage, temper investor enthusiasm and limit significant stock appreciation.
Show more
Updated on 9/17/2026
Anixa Biosciences (ANIX) stock has gained about 5% since 5/31/2026 because of the following key factors:
1. Continued Clinical Development without Major Catalysts.
Anixa Biosciences reported positive final Phase 1 data for its breast cancer vaccine, demonstrating that all primary endpoints were met, including safety, and that protocol-defined immune responses were generated in 74% of participants. Preparations for a Phase 2 trial are underway. Similarly, its ovarian cancer CAR-T therapy (lira-cel) advanced to the fifth and highest dose cohort in its ongoing Phase 1 clinical trial, with no dose-limiting toxicities observed to date and several patients surpassing one year of survival, including one beyond 28 months. While these are positive advancements for early-stage programs and extend patent protection in regions like Australia and Korea, they represent incremental progress rather than definitive commercial breakthroughs, leading to a largely stable stock price without significant upward momentum.
2. Persistent Lack of Revenue and Ongoing Operating Losses.
As a clinical-stage biotechnology company, Anixa Biosciences continued to report no revenue for fiscal Q3 2026 (ended July 31, 2026), a trend unchanged from the year-ago quarter. The company posted a net loss attributable to common shareholders of $(2.61) million for fiscal Q3 2026 and a net loss of $(7.69) million for the nine months ended July 31, 2026. Management has stated that near-term revenue from its therapeutics or vaccine programs is not anticipated. This ongoing lack of revenue and continued financial losses, typical for companies in this development stage, temper investor enthusiasm and limit significant stock appreciation.
3. Mixed Analyst Sentiment Despite High Price Targets.
Analyst opinions on Anixa Biosciences during this period presented a mixed, albeit generally positive, outlook. While some analysts maintained a "Strong Buy" rating with an average 12-month price target of $10.00, reflecting a substantial potential upside, other firms like Zacks Research downgraded the stock from "strong-buy" to "hold" in August 2026, and Wall Street Zen upgraded it from "sell" to "hold" in June 2026. This divergence in professional assessment, with some analysts seeing significant long-term potential but others adopting a more cautious "hold" stance, likely contributed to the stock's consolidation at current levels as investors processed the varying perspectives.
4. Sufficient but Limited Cash Position for Extended Development.
Anixa Biosciences reported approximately $13.9 million in cash, cash equivalents, and short-term investments as of July 31, 2026. The company's management expects this existing funding to be sufficient for more than 12 months. While this cash position provides stability and mitigates immediate concerns about dilution or operational halts, it also highlights that the company remains dependent on its existing capital or future financing for the prolonged and costly development phases of its clinical programs. This financial posture, common for biotechs, often results in a plateaued stock performance until more advanced clinical data or commercialization pathways become clear.
Show less
Anixa Biosciences (ANIX) stock has gained about 5% since 5/31/2026 because of the following key factors:
1. Continued Clinical Development without Major Catalysts.
Anixa Biosciences reported positive final Phase 1 data for its breast cancer vaccine, demonstrating that all primary endpoints were met, including safety, and that protocol-defined immune responses were generated in 74% of participants. Preparations for a Phase 2 trial are underway. Similarly, its ovarian cancer CAR-T therapy (lira-cel) advanced to the fifth and highest dose cohort in its ongoing Phase 1 clinical trial, with no dose-limiting toxicities observed to date and several patients surpassing one year of survival, including one beyond 28 months. While these are positive advancements for early-stage programs and extend patent protection in regions like Australia and Korea, they represent incremental progress rather than definitive commercial breakthroughs, leading to a largely stable stock price without significant upward momentum.
2. Persistent Lack of Revenue and Ongoing Operating Losses.
As a clinical-stage biotechnology company, Anixa Biosciences continued to report no revenue for fiscal Q3 2026 (ended July 31, 2026), a trend unchanged from the year-ago quarter. The company posted a net loss attributable to common shareholders of $(2.61) million for fiscal Q3 2026 and a net loss of $(7.69) million for the nine months ended July 31, 2026. Management has stated that near-term revenue from its therapeutics or vaccine programs is not anticipated. This ongoing lack of revenue and continued financial losses, typical for companies in this development stage, temper investor enthusiasm and limit significant stock appreciation.
3. Mixed Analyst Sentiment Despite High Price Targets.
Analyst opinions on Anixa Biosciences during this period presented a mixed, albeit generally positive, outlook. While some analysts maintained a "Strong Buy" rating with an average 12-month price target of $10.00, reflecting a substantial potential upside, other firms like Zacks Research downgraded the stock from "strong-buy" to "hold" in August 2026, and Wall Street Zen upgraded it from "sell" to "hold" in June 2026. This divergence in professional assessment, with some analysts seeing significant long-term potential but others adopting a more cautious "hold" stance, likely contributed to the stock's consolidation at current levels as investors processed the varying perspectives.
4. Sufficient but Limited Cash Position for Extended Development.
Anixa Biosciences reported approximately $13.9 million in cash, cash equivalents, and short-term investments as of July 31, 2026. The company's management expects this existing funding to be sufficient for more than 12 months. While this cash position provides stability and mitigates immediate concerns about dilution or operational halts, it also highlights that the company remains dependent on its existing capital or future financing for the prolonged and costly development phases of its clinical programs. This financial posture, common for biotechs, often results in a plateaued stock performance until more advanced clinical data or commercialization pathways become clear.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
5/31/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| ANIX | 2.6% | |
| Market (SPY) | 0.9% | 16.3% |
| Sector (XLV) | 12.7% | 18.7% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| ANIX | -7.0% | |
| Market (SPY) | 11.6% | 32.3% |
| Sector (XLV) | 5.5% | 26.8% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2025 to 9/20/2026| Return | Correlation | |
|---|---|---|
| ANIX | -7.4% | |
| Market (SPY) | 19.4% | 28.4% |
| Sector (XLV) | 24.1% | 12.0% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2023 to 9/20/2026| Return | Correlation | |
|---|---|---|
| ANIX | -24.5% | |
| Market (SPY) | 75.6% | 24.7% |
| Sector (XLV) | 32.3% | 14.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ANIX Return | -3% | 43% | -9% | -40% | 34% | -12% | -10% |
| Peers Return | -7% | 32% | 41% | -1% | 13% | 18% | 127% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| ANIX Win Rate | 42% | 58% | 58% | 33% | 50% | 33% | |
| Peers Win Rate | 42% | 67% | 58% | 50% | 83% | 64% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| ANIX Max Drawdown | -60% | -39% | -52% | -56% | -40% | -31% | |
| Peers Max Drawdown | -27% | -19% | -12% | -23% | -29% | -15% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, APMD, ATTO, BLSM, BRVE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)
How Low Can It Go
| Event | ANIX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -17.1% | -18.8% |
| % Gain to Breakeven | 20.6% | 23.1% |
| Time to Breakeven | 55 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -22.3% | -9.5% |
| % Gain to Breakeven | 28.8% | 10.5% |
| Time to Breakeven | 26 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -29.6% | -6.7% |
| % Gain to Breakeven | 42.1% | 7.1% |
| Time to Breakeven | 185 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -17.2% | -24.5% |
| % Gain to Breakeven | 20.8% | 32.4% |
| Time to Breakeven | 45 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -60.4% | -33.7% |
| % Gain to Breakeven | 152.6% | 50.9% |
| Time to Breakeven | 284 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -33.0% | -19.2% |
| % Gain to Breakeven | 49.3% | 23.8% |
| Time to Breakeven | 39 days | 105 days |
In The Past
Anixa Biosciences's stock fell -17.1% during the 2025 US Tariff Shock. Such a loss loss requires a 20.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ANIX | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -22.3% | -9.5% |
| % Gain to Breakeven | 28.8% | 10.5% |
| Time to Breakeven | 26 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -29.6% | -6.7% |
| % Gain to Breakeven | 42.1% | 7.1% |
| Time to Breakeven | 185 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -60.4% | -33.7% |
| % Gain to Breakeven | 152.6% | 50.9% |
| Time to Breakeven | 284 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -33.0% | -19.2% |
| % Gain to Breakeven | 49.3% | 23.8% |
| Time to Breakeven | 39 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -75.2% | -3.7% |
| % Gain to Breakeven | 302.8% | 3.9% |
| Time to Breakeven | 95 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -55.2% | -12.2% |
| % Gain to Breakeven | 123.4% | 13.9% |
| Time to Breakeven | 185 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -37.6% | -6.8% |
| % Gain to Breakeven | 60.3% | 7.3% |
| Time to Breakeven | 12 days | 15 days |
In The Past
Anixa Biosciences's stock fell -17.1% during the 2025 US Tariff Shock. Such a loss loss requires a 20.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Anixa Biosciences (ANIX)
Anixa Biosciences, Inc. is a biotechnology company focused on developing innovative therapies and vaccines to address critical unmet needs in both oncology and infectious diseases. The company's pipeline includes programs designed to treat existing conditions as well as prevent future ones, utilizing advanced biotechnological approaches to tackle severe health challenges.
Anixa's therapeutic programs include the development of a chimeric endocrine receptor T-cell technology specifically for ovarian cancer, a novel form of CAR-T. The company is also discovering anti-viral drug candidates for COVID-19 through a collaboration with MolGenie GmbH, aiming to inhibit specific viral protein functions. On the vaccine front, Anixa is advancing a vaccine against triple-negative breast cancer and a preventative vaccine for ovarian cancer. Additionally, the company is developing general immuno-therapy drugs targeting various cancers, serving patients who require specialized and advanced medical interventions for these diseases.
AI Analysis | Feedback
1. Kite Pharma for ovarian cancer and preventative oncology vaccines.
2. Moderna, but focused on cancer vaccines and novel COVID-19 antivirals.
AI Analysis | Feedback
```html
- Chimeric Endocrine Receptor T-cell (CER-T) therapy: A novel CAR-T technology in development for the treatment of ovarian cancer.
- Anti-viral drug candidates for COVID-19: Drug candidates being discovered and developed to inhibit specific protein functions of the COVID-19 virus.
- Triple Negative Breast Cancer Vaccine: A vaccine currently under development targeting triple negative breast cancer.
- Ovarian Cancer Preventative Vaccine: A preventative vaccine being developed to protect against ovarian cancer.
AI Analysis | Feedback
Anixa Biosciences (ANIX) is a development-stage biotechnology company focused on the research, discovery, and development of therapies and vaccines for oncology and infectious diseases. Based on the provided description, the company is primarily engaged in preclinical and clinical development programs. It has not yet commercialized any products, and therefore, it does not have major customers in the traditional sense of selling products or services to individuals or other companies. Its current activities revolve around scientific research, clinical trials, and potential future collaborations or licensing agreements with larger pharmaceutical partners if its drug candidates prove successful.
AI Analysis | Feedback
null
AI Analysis | Feedback
Amit Kumar, Ph.D. Chairman & Chief Executive Officer
Dr. Kumar is an experienced investor, founder, director, and CEO of numerous public and private technology enterprises. He successfully took CombiMatrix Corporation public and led it for a decade while it was listed on the NASDAQ Global Market. He has also worked in venture capital with OAK Investment Partners and served as an advisor to various investment funds, venture capital firms, and Fortune 500 companies. From 2002 to 2008, he was on the Board of Directors of Acacia Research Corporation. Currently, Dr. Kumar also serves on the Boards of other public and private companies and has been a Board member of the American Cancer Society since 2016. He holds an AB in Chemistry from Occidental College, a Ph.D. from Caltech, and completed a post-doctoral fellowship at Harvard after graduate studies at Stanford University and Caltech.
Michael Catelani President, COO & CFO
Mr. Catelani brings over 30 years of extensive experience in finance and operations management. He cofounded Tacere Therapeutics, Inc., a privately held biotech company, where he served as Chairman, President & Chief Financial Officer until its successful sale. Before Tacere, he was on the Board of Directors and held the Chief Financial Officer role at Benitec Biopharma Limited, a biotech company listed on the Australian Stock Exchange. His career also includes serving as Vice President and Chief Financial Officer at Axon Instruments, a U.S. corporation publicly traded on the Australian Stock Exchange, and as Vice President of Finance for Media Arts Group, Inc., an NYSE-listed company. Mr. Catelani has advised and managed several early-stage start-ups across various sectors, including biotechnology, and has acted as a contract CFO for established biotech firms. He began his career at Ernst & Young and is a CPA (Inactive). He earned his BS in business administration with a concentration in accountancy from Sacramento State University and an MBA from the University of California, Davis.
Pamela D. Garzone, Ph.D. Chief Development Officer
Dr. Garzone is a highly accomplished senior pharmaceutical executive with more than 25 years of diverse industry experience. She is recognized for her strategic, scientific, clinical, and regulatory leadership in drug development. Before joining Anixa, Dr. Garzone held executive positions in clinical development at several companies, including Calibr, a division of the Scripps Research Institute, and Pfizer. She also held roles of increasing responsibility at Elan Pharmaceuticals and Genetics Institute, having started her industry career at Genentech. Prior to her industry tenure, she was an Assistant Professor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy. She holds a B.S. degree in Pharmacy from Purdue University, an M.S. in Pharmacy Practice, and a Ph.D. in Clinical Science from the University of Pittsburgh.
AI Analysis | Feedback
The key risks to Anixa Biosciences (ANIX) are primarily associated with the inherent uncertainties of biotechnology development, its pre-revenue stage, and the competitive landscape.
Here are the key risks:
1. Clinical Trial and Regulatory Approval Failure: As a biotechnology company focused on developing novel therapies and vaccines for oncology and infectious diseases, Anixa Biosciences' success is contingent upon the successful outcome of extensive and costly clinical trials and subsequent regulatory approval. The development process is highly speculative, with a significant risk that product candidates may fail to demonstrate efficacy or safety, experience delays in patient enrollment, or encounter other setbacks during clinical trials, thereby preventing or delaying regulatory approval and potential commercialization. The company has not yet generated revenue from product sales, making the progress and results of these trials critical to its future viability.
2. Need for Additional Funding and Shareholder Dilution: Anixa Biosciences is a pre-revenue company with substantial ongoing research and development expenses. The development of therapies and vaccines requires significant capital, and the company will likely need to raise additional funding in the future. This continued need for capital, often through equity offerings, carries a significant risk of diluting existing shareholders' ownership interests and could adversely impact the stock price. Anixa has an accumulated deficit highlighting the capital intensity of its operations.
3. Competition and Reliance on Collaborations and Intellectual Property: The fields of oncology and infectious diseases are highly competitive, with numerous pharmaceutical and biotechnology companies developing and commercializing new treatments and vaccines. Anixa's ability to compete depends on the efficacy, safety, and market acceptance of its product candidates, as well as its ability to protect its intellectual property. The company's business model also relies on strategic collaborations for aspects like manufacturing and commercialization, and the termination or disputes regarding these agreements or intellectual property licenses could severely hinder its development and sales efforts.
AI Analysis | Feedback
The highly competitive and rapidly evolving market for COVID-19 therapeutics, where major pharmaceutical companies have already launched effective treatments (e.g., Pfizer's Paxlovid and Merck's Lagevrio) and continue to develop next-generation antiviral candidates. These established and emerging therapies from well-resourced competitors could diminish the market opportunity or even render Anixa's COVID-19 anti-viral drug candidates less competitive or obsolete if they do not demonstrate superior efficacy, safety, or unique advantages.
AI Analysis | Feedback
Anixa Biosciences (ANIX) is developing therapies and vaccines for oncology and infectious diseases. The addressable markets for their main products or services are as follows:
* Chimeric Endocrine Receptor T-cell Technology for Ovarian Cancer: While a specific market size for CAR-T technology exclusively for ovarian cancer is not readily available, the broader ovarian cancer treatment market is substantial. The global ovarian cancer drugs market was valued at approximately USD 3.84 billion in 2024 and is projected to reach around USD 7.34 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 6.7% from 2025 to 2034. North America held the largest revenue share in the global ovarian cancer market in 2024, with the U.S. ovarian cancer drugs market size estimated at USD 1.3 billion in 2024, projected to reach approximately USD 2.4 billion by 2034. The global CAR T-cell therapy market, covering various indications including some solid tumors, was estimated at USD 5.21 billion in 2025 and is predicted to grow to approximately USD 23.25 billion by 2034.
* Anti-viral Drug Candidates for COVID-19: The global COVID-19 therapeutics market was valued at US$ 30.7 billion in 2021 and is projected to reach more than US$ 16.2 billion by the end of 2031. The specific antiviral drugs for COVID-19 market was valued at $15.23 billion in 2025 and is projected to grow to $33.17 billion in 2030. North America held the largest market share in the COVID-19 therapeutics market, with a market size of USD 13.02 billion in 2025.
* Vaccine Against Triple-Negative Breast Cancer: A dedicated market size for a triple-negative breast cancer vaccine is not individually reported. However, the global triple-negative breast cancer treatment market was valued at USD 1.06 billion in 2024 and is expected to reach USD 1.63 billion by 2032. Another report estimated the global triple-negative breast cancer treatment market at USD 4.62 billion in 2025, projected to reach USD 7.3 billion by 2035. North America leads the global triple-negative breast cancer market. The broader global cancer vaccine market, which includes both preventative and therapeutic vaccines, was estimated at USD 11.21 billion in 2024 and is projected to reach USD 36.32 billion by 2035.
* Preventative Vaccine Against Ovarian Cancer: A specific market size for a preventative ovarian cancer vaccine is not yet established, as this is an emerging area of development. However, research for a preventative ovarian cancer vaccine is underway. The overall global cancer vaccine market, encompassing preventative and therapeutic approaches, was estimated at USD 11.21 billion in 2024 and is projected to reach USD 36.32 billion by 2035.
AI Analysis | Feedback
Anixa Biosciences (ANIX), a biotechnology company focused on oncology and infectious diseases, is currently a clinical-stage company with no revenue from its therapeutic or vaccine programs. Future revenue growth over the next 2-3 years is expected to be driven by the successful advancement and potential commercialization or out-licensing of its pipeline assets. The key drivers include:
- Advancement and Potential Commercialization of Ovarian Cancer CAR-T Therapy: The company's chimeric endocrine receptor T-cell technology for ovarian cancer is currently in a Phase 1 clinical trial, with encouraging patient survival observations and regulatory approval enabling dose escalation. The successful progression of this therapy through later-stage clinical trials (Phase 2, Phase 3), subsequent regulatory approval, and eventual market launch would be a significant driver of future revenue. The approval of "liraltagene autoleucel" as the non-proprietary name for their CAR-T therapy also signifies progress towards future commercialization.
- Advancement and Potential Commercialization of the Preventative Breast Cancer Vaccine: Anixa's preventative vaccine against triple-negative breast cancer has successfully completed Phase 1 clinical trials, demonstrating that all primary endpoints were met and showing protocol-defined immune responses in 74% of subjects. The company is preparing for a Phase 2 trial and intends to engage regulators regarding a potential combination treatment. Successful development, regulatory approval, and market introduction of this vaccine would be a major revenue catalyst, especially given the breast cancer market is projected to grow substantially.
- Establishment of Licensing Agreements and Strategic Partnerships: Anixa Biosciences aims to generate non-dilutive revenue through strategic licensing agreements and early-stage partnerships with larger biotechnology and pharmaceutical firms. These collaborations could provide upfront license fees, milestone payments triggered by the achievement of specific developmental or regulatory targets, and ultimately, royalties or revenue shares upon product commercialization. This collaborative business model is integral to funding ongoing development and positioning its programs for market entry.
- Progression of Other Early-Stage Cancer Vaccine Candidates: Beyond its lead programs, Anixa has initiated development programs for vaccines targeting other high-incidence cancers, including lung, prostate, and colon. Although these are in earlier stages of development, significant progress, such as entering clinical trials, or securing specific development funding or partnerships for these candidates, could contribute to future revenue growth within the specified timeframe.
AI Analysis | Feedback
Share Repurchases
- Anixa Biosciences announced a share repurchase program of up to $5 million on July 15, 2024.
- As of the announcement date, no shares had been repurchased under this program.
- The authorized repurchase program was set to expire in twelve months from its announcement date.
Share Issuance
- Anixa Biosciences had 33,376,690 shares of common stock outstanding as of January 12, 2026, and 33,527,858 shares as of March 9, 2026.
- The company raised $1.625 million through an at-the-market stock offering as of March 9, 2026.
- An existing at-the-market equity program permits up to $100 million of future common stock sales.
Inbound Investments
- Anixa Biosciences collaborates with Moffitt Cancer Center for its ovarian cancer chimeric endocrine receptor T-cell (CAR-T) technology program.
- The company also partners with Cleveland Clinic for the development of its breast and ovarian cancer vaccine technologies.
- Cleveland Clinic is entitled to royalties and other commercialization revenues from Anixa related to these vaccine technologies.
Capital Expenditures
- Anixa Biosciences's latest trailing twelve months (TTM) Capital Expenditure (CapEx) CAGR 1YRS stands at 0%. Over the past five years, the average CapEx CAGR 1YRS has also been 0%.
- Research and development expenses for the first quarter ended January 31, 2026, were $1.1 million, primarily for breast cancer vaccine development and CAR-T costs.
- For Q1 2025, research and development expenses increased by approximately 15% to $1.552 million, mainly due to ongoing clinical programs.
Peer Outperformance in Biotechnology
ANIX has outperformed 67% of its 363 Biotechnology peers over 5Y. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that ANIX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
45%
of 455 industry peers · -16.1% return
3Y
51%
of 402 industry peers · -18.5% return
5Y
67%
of 363 industry peers · -42.2% return
null
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is ANIX's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 16.2% | 43.2% | 90.1% | CAH 392% · MCK 346% · COR 168% |
| Managed Health Care | 8 | 40.4% | -5.3% | 2.3% | OSCR 84% · HQY 56% · ELV 17% |
| Health Care Services | 20 | 21.1% | 37.6% | -0.3% | HIMS 239% · RDNT 173% · DGX 76% |
| Health Care Facilities | 24 | 6.0% | 6.5% | -4.5% | NHC 271% · THC 261% · ENSG 129% |
| Health Care Equipment | 50 | -2.7% | -0.2% | -21.1% | POCI 11050% · UFPT 341% · GKOS 222% |
| Pharmaceuticals | 62 | -10.5% | 14.8% | -38.6% | LQDA 2472% · INDV 1099% · ETON 1051% |
| Health Care Supplies | 12 | 14.1% | -8.9% | -39.7% | LNTH 287% · HAE 54% · MMSI 20% |
| Life Sciences Tools & Services | 109 | 4.3% | -11.3% | -68.4% | SNWV 1757% · MEDP 231% · NTRA 199% |
| Health Care Technology | 21 | -25.8% | -52.6% | -79.2% | SPOK 68% · HSTM 3% · VEEV -13% |
| Biotechnology ← | 364 | 0.6% | -21.7% | -79.4% | CELZ 1280% · DNTH 1221% · ELVN 1069% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 27.37 |
| Mkt Cap | 129.0 |
| Rev LTM | 0 |
| Op Inc LTM | -31 |
| FCF LTM | -64 |
| FCF 3Y Avg | 1,957 |
| CFO LTM | -62 |
| CFO 3Y Avg | 2,398 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.2% |
| Rev Chg 3Y Avg | 9.8% |
| Rev Chg Q | 12.5% |
| QoQ Delta Rev Chg LTM | 3.0% |
| Op Inc Chg LTM | 2,497.9% |
| Op Inc Chg 3Y Avg | 792.2% |
| Op Mgn LTM | 19.9% |
| Op Mgn 3Y Avg | 23.9% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | -71.5% |
| CFO/Rev 3Y Avg | 19.6% |
| FCF/Rev LTM | -71.5% |
| FCF/Rev 3Y Avg | 15.7% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2021 | 2019 |
|---|---|---|---|---|---|
| Cancer Vaccines | 0 | 0 | |||
| Chimeric antigen receptor-T cell (CAR-T) Therapeutics | 0 | 0 | |||
| Other | 0 | 0 | 0 | ||
| Patent licensing | 1 | 0 | |||
| Total | 0 | 0 | 0 | 1 | 0 |
| $ Mil | 2005 | 2004 |
|---|---|---|
| Flat-Panel Display | -2 | -2 |
| Encryption Products | -3 | -2 |
| Total | -4 | -3 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Other | -0 | -0 | -1 | -0 | 0 |
| Chimeric antigen receptor-T cell (CAR-T) Therapeutics | -4 | -6 | -4 | -6 | -6 |
| Cancer Vaccines | -7 | -8 | -5 | -5 | -5 |
| Anti-Viral Therapeutics | -3 | -3 | |||
| Total | -12 | -14 | -10 | -14 | -13 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cancer Vaccines | 10 | 13 | 17 | 9 | 13 |
| Chimeric antigen receptor-T cell (CAR-T) Therapeutics | 6 | 9 | 8 | 17 | 15 |
| Other | 0 | 0 | 1 | 0 | 1 |
| Anti-Viral Therapeutics | 4 | 7 | |||
| Total | 16 | 22 | 26 | 30 | 36 |
Price Behavior
Price Behavior
| Market Price | $2.77 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 07/10/2015 | |
| Distance from 52W High | -46.9% | |
| 50 Days | 200 Days | |
| DMA Price | $3.30 | $3.09 |
| DMA Trend | down | up |
| Distance from DMA | -15.9% | -10.4% |
| 3M | 1YR | |
| Volatility | 64.6% | 71.9% |
| Downside Capture | 52.70 | 180.71 |
| Upside Capture | 20.89 | 129.65 |
| Correlation (SPY) | 10.1% | 29.1% |
ANIX Betas & Captures as of 8/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.54 | 0.05 | 0.58 | 1.28 | 1.58 | 1.12 |
| Up Beta | -1.44 | -0.11 | 1.32 | 1.38 | 1.62 | 1.00 |
| Down Beta | -2.23 | -1.55 | 0.82 | 0.95 | 1.78 | 1.19 |
| Up Capture | 149% | 69% | 71% | 142% | 179% | 107% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 6 | 17 | 26 | 54 | 111 | 329 |
| Down Capture | 296% | 26% | -35% | 131% | 137% | 107% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 13 | 22 | 34 | 66 | 127 | 387 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANIX | |
|---|---|---|---|---|
| ANIX | -17.4% | 71.7% | 0.03 | - |
| Sector ETF (XLV) | 24.4% | 16.1% | 1.16 | 14.7% |
| Equity (SPY) | 16.9% | 12.9% | 0.94 | 29.1% |
| Gold (GLD) | 19.1% | 29.3% | 0.60 | 19.5% |
| Commodities (DBC) | 46.3% | 20.6% | 1.73 | -0.4% |
| Real Estate (VNQ) | 4.9% | 13.6% | 0.10 | 9.8% |
| Bitcoin (BTCUSD) | -30.6% | 44.3% | -0.70 | 30.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANIX | |
|---|---|---|---|---|
| ANIX | -11.3% | 71.4% | 0.13 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.24 | 15.9% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 23.8% |
| Gold (GLD) | 19.1% | 18.8% | 0.83 | 9.3% |
| Commodities (DBC) | 11.2% | 19.5% | 0.45 | 4.8% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | 13.2% |
| Bitcoin (BTCUSD) | 12.5% | 52.5% | 0.42 | 20.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANIX | |
|---|---|---|---|---|
| ANIX | -2.4% | 93.5% | 0.38 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 14.6% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | 18.8% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | 6.6% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | 8.2% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.18 | 13.6% |
| Bitcoin (BTCUSD) | 62.6% | 66.2% | 1.02 | 11.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 07/31/2026 | 09/09/2026 | 10-Q |
| 04/30/2026 | 06/10/2026 | 10-Q |
| 01/31/2026 | 03/09/2026 | 10-Q |
| 10/31/2025 | 01/12/2026 | 10-K |
| 07/31/2025 | 09/10/2025 | 10-Q |
| 04/30/2025 | 05/28/2025 | 10-Q |
| 01/31/2025 | 03/11/2025 | 10-Q |
| 10/31/2024 | 01/10/2025 | 10-K |
| 07/31/2024 | 09/06/2024 | 10-Q |
| 04/30/2024 | 06/04/2024 | 10-Q |
| 01/31/2024 | 03/12/2024 | 10-Q |
| 10/31/2023 | 01/16/2024 | 10-K |
| 07/31/2023 | 09/06/2023 | 10-Q |
| 04/30/2023 | 06/14/2023 | 10-Q |
| 01/31/2023 | 03/17/2023 | 10-Q |
| 10/31/2022 | 01/04/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 07/31/2026 | 09/09/2026 | 10-Q |
| 04/30/2026 | 06/10/2026 | 10-Q |
| 01/31/2026 | 03/09/2026 | 10-Q |
| 10/31/2025 | 01/12/2026 | 10-K |
| 07/31/2025 | 09/10/2025 | 10-Q |
| 04/30/2025 | 05/28/2025 | 10-Q |
| 01/31/2025 | 03/11/2025 | 10-Q |
| 10/31/2024 | 01/10/2025 | 10-K |
| 07/31/2024 | 09/06/2024 | 10-Q |
| 04/30/2024 | 06/04/2024 | 10-Q |
| 01/31/2024 | 03/12/2024 | 10-Q |
| 10/31/2023 | 01/16/2024 | 10-K |
| 07/31/2023 | 09/06/2023 | 10-Q |
| 04/30/2023 | 06/14/2023 | 10-Q |
| 01/31/2023 | 03/17/2023 | 10-Q |
| 10/31/2022 | 01/04/2023 | 10-K |
| 07/31/2022 | 09/09/2022 | 10-Q |
| 04/30/2022 | 06/10/2022 | 10-Q |
| 01/31/2022 | 03/11/2022 | 10-Q |
| 10/31/2021 | 01/04/2022 | 10-K |
| 07/31/2021 | 09/01/2021 | 10-Q |
| 04/30/2021 | 06/10/2021 | 10-Q |
| 01/31/2021 | 03/11/2021 | 10-Q |
| 10/31/2020 | 01/07/2021 | 10-K |
| 07/31/2020 | 09/08/2020 | 10-Q |
| 04/30/2020 | 06/09/2020 | 10-Q |
| 01/31/2020 | 03/09/2020 | 10-Q |
| 10/31/2019 | 01/09/2020 | 10-K |
Insider Activity
Updated 9/14/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 9142026 | 2.75 | 3,000 | 8,250 | 1,828,750 | Form |
| 2 | Titterton, Lewis H JR | Direct | Buy | 9142026 | 2.73 | 10,000 | 27,300 | 2,721,720 | Form | |
| 3 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 9112026 | 2.76 | 5,000 | 13,800 | 1,827,120 | Form |
| 4 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 8032026 | 3.47 | 5,000 | 17,350 | 2,279,790 | Form |
| 5 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 7282026 | 3.44 | 5,000 | 17,200 | 2,242,880 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 9142026 | 2.75 | 3,000 | 8,250 | 1,828,750 | Form |
| 2 | Titterton, Lewis H JR | Direct | Buy | 9142026 | 2.73 | 10,000 | 27,300 | 2,721,720 | Form | |
| 3 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 9112026 | 2.76 | 5,000 | 13,800 | 1,827,120 | Form |
| 4 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 8032026 | 3.47 | 5,000 | 17,350 | 2,279,790 | Form |
| 5 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 7282026 | 3.44 | 5,000 | 17,200 | 2,242,880 | Form |
| 6 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 7272026 | 3.37 | 3,188 | 10,744 | 2,180,390 | Form |
| 7 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 7272026 | 3.73 | 3,000 | 11,190 | 2,401,419 | Form |
| 8 | Titterton, Lewis H JR | Direct | Buy | 7202026 | 3.47 | 12,000 | 41,640 | 3,424,775 | Form | |
| 9 | Titterton, Lewis H JR | Direct | Buy | 7162026 | 3.28 | 2,797 | 9,174 | 3,197,892 | Form | |
| 10 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 7132026 | 3.04 | 5,000 | 15,200 | 1,932,868 | Form |
| 11 | Kumar, Amit | Chief Executive Officer | Direct | Buy | 6162026 | 2.50 | 21,000 | 52,500 | 1,577,030 | Form |
| 12 | Baskies, Arnold M | Direct | Buy | 1292026 | 3.04 | 10,000 | 30,400 | 410,400 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 9/20/2026